Contrast A A A Link to Twitter page

Vaccine types and patient choice

Posted in Our priorities


Vaccine types and patient choice Frequently asked questions

What vaccines for COVID-19 are currently available?

Following extensive trials, four vaccines, Pfizer, Oxford-AstraZeneca, Moderna and Janssen, have been approved by regulators. The first three are available in England now; Janssen will be available later this year. Availability of the different types of vaccine may vary according to different locations and at different times. In Shropshire, Telford and Wrekin, we currently have Pfizer and Oxford-AstraZeneca vaccines available.


Can I choose the type of vaccine I have?

All Covid-19 vaccines provided by the NHS have been approved and they have passed the Medical and Health Regulatory Agency’s (MHRA’s) very strict tests on safety and efficacy. 

You can’t choose which type of vaccine you have; you will have the vaccine that is available in your location at the time when you are eligible. There are a certain number of exceptions to this and the latest national guidance advises under 40 year olds, pregnant women and people with a small number of very specific conditions* to have an alternative to the Astra Zeneca vaccine where possible.  In certain cases, people who are at high risk within the groups mentioned above might decide, after discussion with their GP and weighing up the benefits and the risks, to go ahead with the Astra Zeneca vaccine if they are able to have this more quickly in their local area.

More information can be found here:

Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement, 7 May 2021 - GOV.UK (

COVID-19 vaccination: a guide for all women of childbearing age, pregnant or breastfeeding - GOV.UK (

The COVID-19 vaccine should not be given to those who have had a previous serious allergic reaction to:

  • a previous dose of the same COVID-19 vaccine
  • any of the vaccine’s contents.


*The Astra Zeneca vaccine should not be given to those with a history of a previous episode of heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2) or to those who experience a clotting episode with concomitant thrombocytopaenia following the first dose of AstraZeneca vaccine.